Scinai Immunotherapeutics Finalizes Highly Dilutive $2.61M Private Placement and Warrant Inducement

summarizeSummary

Scinai Immunotherapeutics secured $2.61 million through a private placement and warrant inducement, providing crucial capital but at a significant cost of dilution to existing shareholders due to discounted pricing and substantial warrant issuance.

check_boxKey Events

• Secured $2.61 Million Gross Proceeds

  The company raised approximately $2.61 million in gross proceeds from a private placement and a warrant inducement transaction.

• Highly Dilutive Private Placement

  The private placement involved the sale of 5,208,333 American Depositary Shares (ADSs) or pre-funded warrants at a purchase price of $0.48 per ADS, a notable discount to the current market price. Investors also received Series A warrants (exercise price $0.48) and Series B warrants (exercise price $0.55) to acquire an aggregate of 10,416,666 additional ADSs.

• Warrant Inducement Transaction

  An existing institutional investor exercised 229,310 ADSs from previously issued warrants at a reduced price of $0.48 per ADS (originally $6.50). In return, the investor received new unregistered warrants to purchase 458,621 ADSs at an exercise price of $0.55 per ADS.

• Financial Advisor Compensation

  A.G.P./Alliance Global Partners, as the exclusive financial advisor, received a 7.0% cash fee and warrants to acquire 260,417 ADSs at an exercise price of $0.53 per ADS.

auto_awesomeAnalysis

Scinai Immunotherapeutics has finalized a private placement and warrant inducement transaction, raising approximately $2.61 million in gross proceeds. This financing is critical for the micro-cap company, providing capital to support its CDMO platform expansion, advance customer programs, and invest in its immunotherapy pipeline. However, the terms are highly dilutive for existing shareholders. The offering price of $0.48 per ADS is a significant discount to the current market price of $0.6001. The transaction involves the immediate issuance of over 5.4 million ADSs and the potential issuance of an additional 11.1 million ADSs upon the exercise of various warrants, representing a substantial increase in the company's outstanding share count. This follows a news announcement on April 24, 2026, and this filing provides the definitive terms.